Staidson BioPharm(SZ:300204) Sou Hu Cai Jing·2025-06-03 08:55Group 1 - The core business of Shuyou Shen (300204) involves the research, production, and marketing of biopharmaceuticals, focusing on innovative drug development [3][4] - The company is recognized as the leading brand in polyethylene glycol products, which enhances its market position [4] - Recent stock price increases are driven by strong concepts in innovative drugs and the performance of the pharmaceutical sector [5] Group 2 - The innovative drug concept remains strong, with the company investing 162 million yuan in R&D for 2024, focusing on infectious diseases and respiratory conditions [5] - The company’s subsidiary, Jiangsu Beijietai Biotechnology Co., Ltd., has applied for priority review of STSP-0601, which has shown significant efficacy in clinical trials for hemophilia treatment [5] - The stock has experienced a notable increase of 66% over three trading days, indicating strong market momentum and positive technical indicators [6]